EUCTR2005-003220-19-SI进行中（未招募）不适用
Multicentricno, odprto, randomizirano klinicno preskušanje faze III z namenom ocene ucinkovitosti zdravila TarcevaTM ali primerjalnih zdravil Alimta® (pemetreksed), oziroma Taxotere® (docetaksel) pri bolnikih s histološko potrjenim napredovalim ali ponavljajocim se (stadij IIIb in neprimerni za kombinirano zdravljenje) ali metastaskim (stadij IV) nedrobnocelicnim rakom pljuc, pri katerih je prišlo do napredovanja bolezni v obdobju kemoterapije na osnovi platine - TITA
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 648
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with histologically documented, locally advanced or recurrent (stage IIIB and not amenable for combined modality treatment) or metastatic (Stage IV) non-small cell lung cancer. Formalin-fixed, paraffin-embedded tumour tissue samples representative of the tumour will be provided to the sponsor within 3 weeks of the patient starting platinum-based chemotherapy. This Is A Mandatory Requirement For Study Entry.
- •2. Patients must have measurable disease according to the RECIST criteria.
- •3. Previous adjuvant or neo-adjuvant treatment is permitted if completed >= 6 months before start of chemotherapy.
- •4. ECOG performance status of 0 – 1
- •5. Written (signed) Informed Consent for use of tumour samples.
- •1. Failure (disease progression) during 1 to 4 cycles of an acceptable, standard, platinum based chemotherapy doublet. This Is A Mandatory Requirement For Study Entry.
- •2. Patients should have recovered from any toxic effects of platinum-based chemotherapy treatment
- •3. ECOG performance status of 0 - 2.
- •4. Patients must be able to take oral medication.
- •5. At least 4 weeks must have elapsed since any prior surgery or radiotherapy. Patients who, in the opinion of the investigator, have fully recovered from surgery in less than 4 weeks may also be considered for the study
- •6. Granulocyte count >= 1,500/mm3 and platelet count > 100,000/mm3. Haemoglobin >= 9.0g/dl.
- •7. SGOT (AST) and SGPT (ALT) < 2.5 x ULN in the absence of liver metastases or up to 5 x ULN in case of liver metastases.
- •8. Alkaline phosphatase (ALP) < 2.5 x ULN. If alkaline phosphatase is > 2.5 x ULN, SGOT (AST) and SGPT (ALT) must be < 1.5 x ULN.
- •9. Serum bilirubin must be =< 1.5 upper limit of normal (ULN).
- •10. Creatinine clearance >= 60 ml/min based on the standard Cockcroft and Gault formula.
- •11. Normal serum calcium.
- •12. For all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before entry into the study (starting Tarceva™ /chemotherapy).
- •13. Patients with reproductive potential must use 2 effective methods of contraception.
- •14. Age 18 (or legal age of consent if greater than 18) or greater.
- •15. Able to comply with study and follow-up procedures.
- •16. Able to provide written (signed) Informed Consent to participate in the TITAN study.
- •17. Patients must be able to effectively read and understand the local language(s) in which the FACT-L (Quality of Life) questionnaires are written.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Prior exposure to agents directed at the HER axis (e.g. gefitinib, cetuximab, trastuzamab).
- •2. Prior agents directed at Alimta® molecular targets (i.e., TS or DHFR inhibitors)
- •3. Prior chemotherapy or therapy with systemic anti-neoplastic therapy (e.g., monoclonal antibody therapy or any experimental therapy) for advanced disease other than the permitted platinum-based chemotherapies. Prior surgery and/or localised irradiation is permitted.
- •4. Any unstable systemic disease (including active infections, significant cardiovascular disease, [including myocardial infarction within the previous year], any significant hepatic, renal or metabolic disease) metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of study medication(s) or that might affect the interpretation of the results or render the patient at high risk from treatment complications.
- •5. Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer).
- •6. Patients are excluded if they have brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation; previously diagnosed and treated CNS metastases or spinal cord compression without evidence of stable disease (clinically stable imaging) for at least 2 months will also cause patients to be excluded.
- •7. Patients who are at risk (in the investigator’s opinion) of transmitting human immunodeficiency virus (HIV) through blood or other body fluids are excluded.
- •8. Any inflammatory changes of the surface of the eye.
- •9. Patients who cannot take oral medication, who require intravenous alimentation, have had prior surgical procedures affecting absorption, or have active peptic ulcer disease.
- •10. Patients who are unable to interrupt acetylic salicylic acid therapy (where aspirin dose is >= 1.3 g/day).
- •11. Nursing mothers.
- •12. Severe hypersensitivity to Tarceva™ or to any of the excipients. (see the Tarceva™ SPC) or to the excipients in Alimta® or Taxotere® (see respective SPCs).
- •13. History of severe hypersensitivity reactions to Taxotere® or to other drugs formulated with polysorbate 80.
研究者
相似试验
招募中
1 期
A prospective, randomized,open, multi-center clinical trial evaluating the efficiency and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)novel coronavirus pneumonia (COVID-19)ITMCTR2000002972Beijing hospital of Traditional Chinese Medicine
已完成
3 期
Recombinant Human Chorionic Gonadotropin in InfertilityCTRI/2014/09/005010Bharat Serums and Vaccines Ltd217
进行中（未招募）
不适用
An open, randomised, prospective, multi-centre, parallel-group trial to compare efficacy and safety of TachoSil versus standard surgical treatment in patients undergoing pulmonary lobectomy for lung malignancy and requiring treatment for air leakage - TachoSil versus standard surgical treatment for air leakage in pulmonary lobectomyEUCTR2004-002380-24-ITYCOMED HEADQUARTER300
招募中
4 期
A randomized, controlled, open, multi-center clinical study on the effectiveness and safety of Kangai injection in the treatment of cancer-induced fatigueTumor patients (lung cancer, rectal cancer, malignant lymphoma, gynecological malignancy)ITMCTR2100004974Jiangsu Provincial Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
An open randomised, prospective, multi-centre, parallel-group trial to compare efficacy and safety of TachoSil versus standard surgical treatment in patients undergoing pulmonary lobectomy for lung malingnancy and requiring treatment for air leakage. - TachoSil versus standard surgical treatment for air leakage in pulmonary lobectomyManagement of pulmonary air leakage following lobectomy in subjects with lung malignancies including metastases.MedDRA version: 8.1Level: PTClassification code 10024741EUCTR2004-002380-24-HUycomed Danmark ApS, International Medical Affairs300